By Jenny A | Posted - Nov 23rd, 2014

 

 

 

 

Myeloma Crowd Research Initiative Targeting High-Risk Myeloma

The Myeloma Crowd Research Initiative (MCRI) is a new approach to funding cancer research; combining the skill and knowledge of leading myeloma specialists with the patient perspective and supportive patient social communities to select and fund promising research projects in myeloma. We succeeded in raising $500,000 for two immunotherapy projects in our first MCRI campaign. 

See What We Funded STAGES

The MCRI received 36 high-quality Letters of Intent from both US and international investigators from major institutions around the world. The proposals spanned research from basic to translational and included clinical studies, all specifically for high-risk patients. The MCRI Scientific Advisory board selected a top 10 proposals. 

The top 10 proposals were invited to submit a full proposal describing the research in detail. Each of the proposals participated on the MyelomaCrowd Radio series in April and May 2015. Patients were able to listen to the shows and ask questions to learn more about the research.

The Scientific Advisory Board and Patient Advisory Boards jointly voted on the top 10 proposals to fund. The MCRI chose 2 research proposals to fund.

We successfully raised $500,000 thanks to patient, family and caregiver donations for two exciting immunotherapy projects.

WINNERS

CAR T-CELL THERAPY  TARGETING CS1 AND BCMA

DR. HERMANN EINSELE & DR. MICHAEL HUDECEK University of Würzburg

Einsele-and-Hudecek-500x300

CAR T-Cells are a hot new area of research in blood cancers. This study takes a patient's own white blood cells from a blood sample and engineers them to target specific receptors - CS1 and BMCA - common proteins found on the surface of myeloma cells. The T Cells are then given back to the patient after a two-week period. CAR T therapy is all at once a cell therapy, gene therapy and immunotherapy. This study will be applicable for high-risk patients who have failed standard myeloma therapies but will also be appropriate for normal risk patients regardless of genetic features.

T-CELL THERAPY WITH AUTOLOGOUS TRANSPLANT

DR. IVAN BORRELLO Johns Hopkins Sidney Kimmell Comprehensive Cancer Center

Dr.-Ivan-Borrello-500x300

Dr. Ivan Borrello is working to create a patient-specific immunotherapy using enhanced T cells from the patient’s own bone marrow, for truly personalized medicine. Using white blood cells from a bone marrow sample, he is able to expand the cells a hundred-fold in the presence of the tumor cells. After these T-Cells are expanded, they are given back to the patient on day 3 or 4 of autologous transplant. When they are reintroduced, they leverage the body's natural process to further expand more immune fighter cells and they target hundreds of proteins that could be causing tumor growth for that patient, not just a single protein. This is an open clinical study today for patients with high-risk genetic features.

Learn More About Their Research FUNDRAISING

Thanks to your generous donations, we raised $500,000 and have distributed the funds to the researchers. One hundred percent (100%) of the funds donated by individuals was applied directly to these research projects. You can continue helping advance a cure by donating to our second MCRI campaign with the theme "Optimizing Myeloma Care." Now we are working to bring the right treatment to the right patient at the right time to identify curative strategies for each type of myeloma patient.

Donate to the MCRIADVISORY BOARDS Scientific Advisory Board Patient Advisory Board Communications Advisory Board

 
Jenny A
About the Author

Jenny A - Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
AmazonSmile
 

MORE MYELOMA CROWD NEWS

Thanks to our site sponsors:

Takeda Oncology Celgene Adaptive biotechnologies